CurrentUnitedHealthcarePolicy N/A

Enspryng (satralizumab-mwge) prior authorization

Defines prior authorization requirements for Enspryng (satralizumab-mwge) for treatment of neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody–positive adults; applies to UnitedHealthcare pharmacy benefit prior authorization programs.

Policy Summary

PayerUnitedHealthcare

PolicyEnspryng (satralizumab-mwge) prior authorization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 17, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis of NMOSD with a positive anti‑AQP4 serologic test; ensure the patient is not receiving excluded concomitant immunotherapies.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

AQP4 positiverequired serologic status

No major immunotherapiesdisallowed concurrent therapies

2025 P 1331-6program id

Coverage Criteria for Enspryng (satralizumab-mwge)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Authorization

Covered when ALL of the following are met:

Initial Authorization: Diagnosis of neuromyelitis optica spectrum disorder (NMOSD).

Initial Authorization: Patient has a positive serologic test for anti-aquaporin-4 (AQP4) antibodies.

ONE of: Anti-IL6 therapy (e.g., Actemra [tocilizumab]).
ONE of: B-cell depletion therapy (e.g., rituximab, Uplizna [inebilizumab-cdon]).
ONE of: Complement inhibitors (e.g., eculizumab, Ultomiris [ravulizumab]).
ONE of: Disease-modifying therapies for multiple sclerosis (e.g., fingolimod, dimethyl fumarate, ocrelizumab).

Reauthorization

Covered when ALL of the following are met:

Reauthorization: Documentation of positive clinical response to Enspryng therapy.

ONE of: Anti-IL6 therapy (e.g., Actemra [tocilizumab]).
ONE of: B-cell depletion therapy (e.g., rituximab, Uplizna [inebilizumab-cdon]).
ONE of: Complement inhibitors (e.g., eculizumab, Ultomiris [ravulizumab]).
ONE of:

Requests for Enspryng will be denied when the patient is receiving Enspryng concomitantly with other major immunomodulatory or immunosuppressive therapies for the same indication. Specifically, concurrent use with any of the following is excluded: anti‑IL6 therapy (e.g., tocilizumab), B‑cell depletion therapy (e.g., rituximab, inebilizumab), complement inhibitors (e.g., eculizumab, ravulizumab), or disease‑modifying therapies for multiple sclerosis (e.g., fingolimod, dimethyl fumarate, ocrelizumab).

When submitting a prior authorization request, ensure the medication history and current therapies are documented; approval requires that the patient is not receiving any of the listed concomitant treatments for the same indication. This restriction applies to both initial authorizations and reauthorizations.

Initial Therapy

Initial therapy is covered when ALL of the following are satisfied:

Initial Therapy: Diagnosis of neuromyelitis optica spectrum disorder (NMOSD).

Initial Therapy: Positive anti-AQP4 serology (patient is AQP4 antibody positive).

Initial Therapy: Patient is not receiving Enspryng concurrently with excluded therapies for the same indication:

Concurrent therapy exclusions (list): Anti-IL6 therapy (e.g., Actemra [tocilizumab]); B-cell depletion therapy (e.g., rituximab, Uplizna [inebilizumab-cdon]); Complement inhibitors (e.g., eculizumab, Ultomiris [ravulizumab]); Disease-modifying therapies for multiple sclerosis (e.g., fingolimod, dimethyl fumarate, ocrelizumab).

Authorization issued for 12 months.

Reauthorization / Continuation Therapy

Reauthorization/Continuation Therapy

Continuation of therapy is approved when ALL of the following are met:

Reauthorization/Continuation Therapy: Documentation of positive clinical response to Enspryng therapy (clinical benefit demonstrated).

Reauthorization/Continuation Therapy: Patient is not receiving Enspryng in combination with any of the following for treatment of the same indication:

Authorization issued for 12 months.

Concomitant therapy exclusions (list): Anti-IL6 therapy (e.g., Actemra [tocilizumab]); B-cell depletion therapy (e.g., rituximab, Uplizna [inebilizumab-cdon]); Complement inhibitors (e.g., eculizumab, Ultomiris [ravulizumab]); Disease-modifying therapies for multiple sclerosis (e.g., fingolimod, dimethyl fumarate, ocrelizumab).

Provider Actions and Documentation Requirements

Prior Authorization

Initial authorization requirements

Prior Authorization Required: Enspryng (satralizumab) initial authorization will be approved only when all required clinical criteria are documented.

Diagnosis: neuromyelitis optica spectrum disorder (NMOSD).
Laboratory: positive serologic test for anti–aquaporin-4 (AQP4) antibodies.
Concomitant therapy exclusion: patient is not receiving Enspryng in combination with any of the following for treatment of the same indication: Anti‑IL6 therapy (e.g., Actemra/tocilizumab); B‑cell depletion therapy (e.g., rituximab, Uplizna/inebilizumab); Complement inhibitors (e.g., eculizumab, Ultomiris/ravulizumab); Disease‑modifying therapies used for multiple sclerosis (e.g., Gilenya/fingolimod, Tecfidera/dimethyl fumarate, Ocrevus/ocrelizumab).
Authorization duration: 12 months.

Note

Automated approval processes

Automated approval and re‑approval processes may be used in some UnitedHealthcare clinical programs.

When applicable, approvals may be issued based solely on previous claim/medication history, diagnosis codes (ICD‑10), and/or internal claim logic.
Use of automated processes varies by program and therapeutic class; medical necessity determinations and supply limits may still apply.

Documentation Required

Required documentation

Required documentation must be submitted to support prior authorization requests.

Clinical documentation of NMOSD diagnosis.
Laboratory documentation confirming positive anti‑AQP4 antibody serology.
Medication history showing absence of excluded concomitant therapies listed under Initial authorization requirements.

Denial Risk

Concomitant therapy exclusion — denial conditions

Authorization will be denied if Enspryng is prescribed in combination with prohibited therapies for the same indication.

Denial/coverage exclusion applies when used with Anti‑IL6 agents, B‑cell depletion therapies, complement inhibitors, or MS disease‑modifying therapies (examples listed above).

Key Definitions

AQP4 antibody positive — definition and relevance to coverage

DefinitionPresence of anti‑aquaporin‑4 (AQP4) antibodies detected by serologic testing.

Role in diagnosisRequired serologic status for the indicated use of Enspryng: NMOSD treatment in adults who are AQP4 antibody positive.

Relevance to coverageCoverage for Enspryng under this policy is limited to patients with a positive anti‑AQP4 antibody test.

Clinical significanceAQP4 antibody positivity identifies patients with NMOSD who are appropriate candidates for IL‑6 receptor antagonist therapy (Enspryng).

Documentation requirementPrior authorization must include documentation of a positive serologic test for anti‑AQP4 antibodies.